Guanethidine |
| Catalog No.GC66202 |
Guanethidine sulphate was synthesized in 1959. Guanethidine is thought to lowing blood pressure by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 55-65-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Guanethidine sulphate was synthesized in 1959. Guanethidine is thought to lowing blood pressure
by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.
Ablation of sympathetic fibers is associated with a loss of rat endothelial cell marker (RECA), but no significant effect of guanethidine was found on the survival of endothelial cells and mesenchymal stem cells in vitro[1].
.
Guanethidine (30 mg/kg, s.c., 1 h) unaffected IL-18 hypernociception in TNFR1(-/-) mice as a sympathetic blocker[2].
.
| Animal Model: | Wild-type (WT) Balb/c,TNFR1(-/-)and IFN-γ-γ(-/-) mice[2]. |
| Dosage: | 30 mg/kg |
| Administration: | Guanethidine (30 mg/kg, s.c., 1 h, diluted in saline) |
| Result: | Pre-treatment with guanethidine (sympathetic blocker) unaffected IL-18 hypernociception in TNFR1(-/-) mice. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *